Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century
Enveda, a Boulder-based biotechnology firm, has raised $311 million in Series E funding from leading AI and biotech investors. The capital will advance its pipeline of oral small-molecule drug candidates for inflammatory bowel disease, asthma, and atopic dermatitis, while expanding AI workflows including collaboration with Anthropic using the Claude model for drug development and GMP record processing.
Listen to Live Briefing
Real-time synthesized voice briefing Β· Live Feeds Desk
- β Enveda raised $311 million in Series E funding from leading AI and biotech investors.
- β The funding pushes Envedas total capital raised since 2019 past $845 million.
- β Enveda is applying artificial intelligence workflows, including collaboration with Anthropic using the Claude model, to streamline drug development and process Good Manufacturing Practice records.
- β The funds will advance Envedas pipeline of oral small-molecule drug candidates targeting inflammatory bowel disease, asthma, and atopic dermatitis.
What changed
Enveda announced a $311 million Series E funding round from leading AI and biotech investors to advance its AI-driven drug development pipeline for inflammatory conditions and respiratory diseases.
Live updates
-
Enveda Closes $311 Million Series E to Accelerate AI-Driven Drug Development
Enveda, a Boulder-based biotechnology firm, has raised $311 million in Series E funding from leading AI and biotech investors. The capital will advance its pipeline of oral small-molecule drug candidates for inflammatory bowel disease, asthma, and atopic dermatitis, while expanding AI workflows including collaboration with Anthropic using the Claude model for drug development and GMP record processing.
Why it matters
The funding pushes Envedas total capital raised since 2019 past $845 million, positioning the company as a significant player in AI-integrated pharmaceutical development. The broader biotech AI sector is experiencing increased investment, with firms like Venomics AI recently raising $2.7 million to enhance their platforms for discovering drugs using artificial intelligence.
What is confirmed
- Enveda raised $311 million in Series E funding from leading AI and biotech investors.
- The funding pushes Envedas total capital raised since 2019 past $845 million.
- Enveda is applying artificial intelligence workflows, including collaboration with Anthropic using the Claude model, to streamline drug development and process Good Manufacturing Practice records.
- The funds will advance Envedas pipeline of oral small-molecule drug candidates targeting inflammatory bowel disease, asthma, and atopic dermatitis.
- Biotech startup Venomics AI raises $2.7 million in funding to enhance its platform for discovering drugs from animal venoms using artificial intelligence and laboratory techniques.
What to watch next
- Phase 1 clinical trial results for Enveda's lead oral small-molecule candidates
- Additional AI platform partnerships announced by Enveda
- Next funding round or acquisition activity in the biotech AI space
confidence 80%Sources used for this update (2)
- entrepreneur.economictimes.indiatimes.com β Venomics AI raises $2.7 Mn to discover drugs from animal venoms
- privateequitylist.com β Top Biotechnology Private Equity Firms (Nov 2026)
-
Enveda Secures $311 Million in Series E Funding
Boulder-based biotechnology firm Enveda has secured $311 million in Series E funding from leading AI and biotech investors. The company is applying artificial intelligence workflows, including collaboration with Anthropic using the Claude model, to streamline drug development and process Good Manufacturing Practice records. This financing pushes Enveda's total capital raised since 2019 past $845 million. The funds will advance its pipeline of oral small-molecule drug candidates targeting inflammatory bowel disease, asthma, and atopic dermatitis.
Why it matters
Artificial intelligence integration aims to modernize pharmaceutical research by automating administrative and compliance burdens. Enveda applies these tools while maintaining human expert oversight for regulatory filings.
What is confirmed
- Enveda secured $311 million in Series E funding from leading AI and biotech investors.
- The company's total capital raised since 2019 has surpassed $845 million.
- Enveda uses the artificial intelligence model Claude from Anthropic to review Good Manufacturing Practice records.
What to watch next
- Clinical trial results for Enveda's oral small-molecule drug candidates targeting inflammatory bowel disease, asthma, and atopic dermatitis.
- Further updates on the integration of AI models in drafting Investigational New Drug applications.
confidence 100%Sources used for this update (2)
- finance.yahoo.com β Penn-BioNTech Innovative Therapeutics Seed Fund Announces First Investment
- newmarketpitch.com β Top AI Drug Discovery Startups by Valuation (2026)
-
Enveda Partners With Anthropic for AI Drug Development
Biotechnology firm Enveda announced results from a collaboration with Anthropic utilizing the artificial intelligence model Claude to streamline drug development processes. Operating out of Boulder, Colorado, Enveda applied AI-enabled workflows to review Good Manufacturing Practice records and draft portions of an Investigational New Drug application while keeping human experts in control. This follows Enveda securing $311 million in Series E funding to advance its pipeline of oral small-molecule drug candidates targeting inflammatory bowel disease, asthma, and atopic dermatitis, pushing its total capital raised since 2019 past $845 million.
Why it matters
Integrating advanced artificial intelligence models into regulatory documentation and manufacturing reviews addresses critical bottlenecks in bringing novel therapeutics to market. Enveda combines mass-spectrometry AI with machine learning to translate natural chemistry into pharmaceutical candidates. The recent capital influx and technology partnership highlight a broader trend of venture and big pharma backing automated drug discovery platforms.
What is confirmed
- Enveda announced results from its collaboration with Anthropic on October 27, 2026, in Boulder, Colorado.
- The partnership utilized Claude to build AI-enabled workflows that review Good Manufacturing Practice records and draft sections of an Investigational New Drug application.
- Enveda previously secured $311 million in Series E funding, bringing its total capital raised since 2019 to over $845 million.
- The company develops oral small-molecule drugs using machine learning and mass-spec AI, including candidates ENV-6946 for inflammatory bowel disease and ENV-294 for asthma and atopic dermatitis.
What to watch next
- Progression of Enveda's drug candidates ENV-6946 and ENV-294 through clinical trials.
- Further expansion of AI-driven automation in regulatory filing processes.
confidence 100%Sources used for this update (8)
- baynews9.com β New federal housing law could reshape manufactured homes in ...
- indexed.vc β Recently Funded Biotech Companies 2026 - indexed.vc
- finance.yahoo.com β Enveda Collaborates with Anthropic to Accelerate Drug Development
- newmarketpitch.com β Who are the top investors in AI drug discovery? β New Market ...
- www.biopharmadive.com β Biotech and Pharma Press Releases | BioPharma Dive
- newmarketpitch.com β Which biotech startup is growing the fastest? β New Market Pitch
- parsers.vc β Enveda Biosciences β Funding, Valuation, Investors, News
- www.synapnews.com β AI Biotech Breakthroughs: Anthropic & Enveda Drug Discovery ...
-
Enveda Raises $311 Million to Advance AI-Driven Drug Discovery
Enveda Therapeutics secured $311 million in Series E funding, expanding its pipeline with AI-discovered drug candidates for inflammatory bowel disease and other conditions. The company uses machine learning and mass-spec AI to develop oral small-molecule drugs. This investment brings its total capital raised since 2019 to over $845 million. Enveda's drug candidates include ENV-6946 for inflammatory bowel disease and ENV-294 for asthma and atopic dermatitis.
Why it matters
The funding reflects investor confidence in AI-driven drug discovery and development. Enveda's approach leverages natural-product chemistry to identify potential treatments. The company's progress is significant amid ongoing efforts to modernize pharmaceutical research and development. The life sciences sector continues to attract substantial investment, with the UK life sciences raising Β£1.23bn in venture capital in the first half of 2025.
What is confirmed
- Enveda Therapeutics raised $311 million in Series E funding.
- Enveda's total capital raised since 2019 is over $845 million.
- The UK life sciences sector raised Β£1.23bn in venture capital in the first half of 2025.
What to watch next
- Enveda's progress in Phase 1 clinical trials for ENV-6946
- the company's plans for ENV-294 in asthma and atopic dermatitis
- future investment trends in AI-driven drug discovery
confidence 100%Sources used for this update (4)
- www.cnbc.com β Biotechnology and Pharmaceuticals - CNBC
- pharmaphorum.com β UK biotech investment "holding firm", says BIA | pharmaphorum
- www.jpmorgan.com β Biopharma and Medtech Deal Reports for Q2 2026 - J.P. Morgan
- www.lawfuel.com β Legal AI News β YC-Backed Crimson Raises Oversubscribed $2.5M ...
-
Enveda advances TL1A inhibitor for inflammatory bowel disease
Enveda Therapeutics is developing ENV-6946, a TL1A inhibitor targeting inflammatory bowel disease. The drug candidate has reached Phase 1 clinical trials. This development expands the company's pipeline beyond its Phase IIa lead candidate, ENV-294, which targets asthma and atopic dermatitis. Enveda uses machine learning and mass-spec AI to mine natural-product chemistry for oral small-molecule drugs. The company recently secured $311 million in Series E funding, bringing its total capital raised since 2019 to over $845 million.
Why it matters
Enveda operates out of Boulder, Colorado, with a valuation of $2 billion. The company focuses on skin conditions and weight loss maintenance using AI-driven discovery. Expanding into digestive system diseases marks a strategic growth in their therapeutic reach.
What is confirmed
- Enveda Therapeutics is developing ENV-6946 as a TL1A inhibitor for inflammatory bowel disease.
- ENV-6946 is currently in Phase 1 clinical trials.
- Enveda has raised more than $845 million since 2019.
- Catalio Capital Management led a $311 million Series E funding round.
What to watch next
- Phase 2 trial results for ENV-294
- Clinical data readouts for ENV-6946 Phase 1 trials
confidence 100%Sources used for this update (4)
- www.biobucks.co β Biotech BD&L Tracker 2026: 156 Licensing & Partnering Deals
- www.biobucks.co β Biotech IPO Tracker 2026: 23 IPOs, ~$7.4B Raised
- www.fiercebiotech.com β Biotech | Fierce Biotech
- synapse.zhihuiya.com β ENV-6946 (ENV-6946) - θ―η©ιΆηΉοΌTL1A_ε¨η ιεΊηοΌηηζ§θ η _δΈε©_...
-
Enveda Secures $311 Million Series E for AI-Driven Natural Product Drug Discovery
Enveda has raised $311 million in Series E funding at a $2 billion valuation to develop oral small-molecule drugs using machine learning and mass-spec AI. Based in Boulder, Colorado, the company mines natural-product chemistry to target skin conditions and weight loss maintenance. Enveda has now raised more than $845 million since 2019. Its lead candidate, ENV-294, is currently in Phase IIa clinical trials for the treatment of asthma and atopic dermatitis. Catalio Capital Management led the latest round with support from several biotech and AI investors.
Why it matters
The company aims to modernize pharmaceutical discovery by applying AI to natural compounds rather than traditional synthetic methods. This approach targets complex inflammatory diseases through oral medications. The funding arrives during a strong Q3 2026 for biotech, where tracked rounds totaled $5.02 billion.
What is confirmed
- Enveda is based in Boulder, Colorado.
- The company uses machine learning and AI to find oral small-molecule drugs from natural samples.
- ENV-294 is in Phase IIa trials for atopic dermatitis and asthma.
- Enveda has raised more than $845 million since 2019.
- Catalio Capital Management led a $311 million Series E funding round at a $2 billion valuation.
What to watch next
- Clinical trial results for ENV-294 in Phase IIa
- Updates on the two other drug candidates currently in human testing
confidence 100%Sources used for this update (4)
- www.thepharmaletter.com β Enveda Biosciences | The Pharma Letter | The Pharmaletter
- jimmyresearch.com β Enveda Biosciences β jimmyΒ·research
- www.biospace.com β Startups - BioSpace
- valueaddvc.com β Q3 2026 Health & Biotech Funding Rounds: Chai's $400M
-
Enveda Secures $311 Million in Series E Financing
Boulder-based clinical-stage biotechnology company Enveda has closed a $311 million Series E funding round at a $2 billion valuation. The company applies artificial intelligence to discover medicines from natural compounds, focusing specifically on skin conditions and weight loss maintenance. Three of its drug candidates are currently undergoing human testing. Catalio Capital Management led the financing, joined by Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, and a notable sovereign wealth fund.
Why it matters
This investment highlights a broader third-quarter venture capital trend where investors remain selective, prioritizing advanced, derisked assets and artificial intelligence drugmakers. Enveda positions itself within this demand by combining computational tools with nature-derived therapeutics. The fresh capital supports ongoing clinical trials for its lead candidates.
What is confirmed
- Enveda raised $311 million in a Series E financing round.
- The funding round valued the company at $2 billion.
- Catalio Capital Management led the financing round.
- Enveda uses artificial intelligence to discover medicines from natural compounds.
- The company focuses its drug discovery efforts on skin conditions and weight loss maintenance.
- Three of Enveda's drug candidates are currently undergoing human testing.
What to watch next
- Progress of Enveda's three drug candidates currently in human testing
- Advancement of the company's AI-driven nature therapeutics pipeline using the new capital
confidence 100%Sources used for this update (8)
- www.investors.com β Biotech And Pharma Stock News - Investor's Business Daily
- www.rttnews.com β Biotech & Pharma News, Stocks, FDA Decision, Clinical Trials - RTTNews
- www.biospace.com β 5 biggest venture capital raises of Q3 2026
- www.frontier-enterprise.com β Enveda raises US$311M from AI, biotech investors
- pharmaphorum.com β News | Timely industry updates for pharma and biotech leaders
- 4lup.com β Enveda Raises $311M to Advance AI-Driven Nature Therapeutics
- peptidestaff.com β Peptide Therapeutics Investment Landscape Q2 2026: Where ...
- pharmaphorum.com β Swiss biotech Noema raises $112m for Roche castoffs
-
Enveda Raises $311 Million for AI-Driven Biotech
Enveda, a Boulder-based biotech firm, has secured $311 million in Series E financing at a $2 billion valuation. The company leverages AI to identify potential drug candidates from natural compounds, focusing on skin conditions and weight loss maintenance. Three of its drug candidates are currently undergoing human testing.
Why it matters
This significant funding round underscores investor confidence in Enveda's innovative approach to drug discovery. The company's use of AI to analyze natural compounds could revolutionize the pharmaceutical industry by accelerating the identification of promising drug candidates. Enveda's progress in bringing these candidates to human trials highlights the potential for AI-driven biotech to transform the sector.
What is confirmed
- Enveda closed a $311 million Series E financing round on September 23, 2026.
- The company's valuation stands at $2 billion.
- Enveda uses AI to identify drug candidates in natural compounds.
- The company targets skin conditions and weight loss maintenance.
- Three of Enveda's drug candidates are undergoing human testing.
What to watch next
- Enveda's progress in human trials for its drug candidates
- Future announcements on additional funding or partnerships
- Regulatory decisions on Enveda's drug candidates
confidence 100%Sources used for this update (4)
- www.dailyfreeman.com β Kingston, NY News, Breaking News, Sports, Weather
- www.dailyfreeman.com β Daily Freeman Obituaries
- eedition.dailyfreeman.com β Your e-Edition is ready - Daily Freeman
- www.dailyfreeman.com β News β Daily Freeman
-
Enveda raises $311M to advance AI-discovered drugs
Enveda, a Boulder-based biotech, closed a $311 million Series E financing round on September 23, 2026, at a $2 billion valuation. The company uses AI to identify drug candidates in natural compounds, targeting skin conditions and weight loss maintenance. Three of its drug candidates are undergoing human testing.
Why it matters
Enveda's approach combines metabolomics, machine learning, and biological assays to discover new medicines. The company aims to bring nature-derived treatments into clinical trials, addressing unmet medical needs.
What is confirmed
- Enveda closed a $311 million Series E financing round on September 23, 2026.
- The company uses a combination of metabolomics, machine learning, automation, and biological assays to investigate complex samples.
- Enveda's AI-discovered drug, ENV-294, showed early relief in atopic dermatitis patients.
- Enveda has been using Bruker's timsTOF technology since 2021.
What to watch next
- Enveda's drug candidates' regulatory approval status
- Results from ongoing clinical trials for ENV-294 and other drug candidates
- Enveda's plans for expanding its target indications
confidence 90%Sources used for this update (4)
- enveda.com β Home - Enveda
- www.bruker.com β Customer Insight Enveda | Bruker
- www.biospace.com β Envedaβs Positive Phase 1B Results for ENV-294, a ... - BioSpace
- www.biopharmatrend.com β Envedaβs AI-Discovered Drug Shows Early Atopic Dermatitis Relief
-
Enveda Secures $311 Million Series E to Advance AI-Derived Therapeutics
Enveda closed a $311 million Series E financing round on September 23, 2026, valuing the Boulder-based biotech at $2 billion. The company employs artificial intelligence to identify drug candidates within natural compounds. Enveda intends to use the capital to advance nature-derived treatments through clinical trials, specifically targeting skin conditions and weight loss maintenance following GLP-1 drug cessation. Currently, three of the company's drug candidates are undergoing human testing but have not yet received regulatory approval.
Why it matters
The funding arrives as venture capital continues to flow into biopharma firms integrating AI for drug discovery. Enveda focuses on bridging the gap between natural chemical diversity and pharmaceutical development. Success depends on whether these AI-identified compounds can prove efficacy and safety in human trials.
What is confirmed
- Enveda closed a $311 million Series E financing round on September 23, 2026.
- The company is based in Boulder and utilizes AI to discover drugs in natural compounds.
- Enveda has a valuation of $2 billion.
- Three drug candidates are being tested in humans but remain unapproved.
What to watch next
- Clinical trial results for the three human-tested drug candidates
- Regulatory filing updates for skin condition or weight loss therapeutics
confidence 100%Sources used for this update (5)
- www.fiercebiotech.com β Fierce Biotech Fundraising Tracker 2026
- dailyaibrief.com β Heidi raises $340 million, Anthropic finds CRISPR like ...
- www.vcaonline.com β Venture Capital & Private Equity News: Deals, Buyouts & Funds
- quasa.io β Enveda raih US$311 juta; tiga kandidat obat masih diuji
- www.fiercebiotech.com β Fierce Biotech News & Reports
-
Enveda raises $311M for AI-driven drug discovery
Enveda, a Boulder-based clinical-stage biotechnology company, closed a $311 million Series E financing round on September 23, 2026, at a $2 billion valuation. The company uses AI to discover drugs in natural compounds and plans to use the capital to push nature-derived therapeutics through clinical trials, focusing on skin conditions and maintaining weight loss after stopping GLP-1 drugs.
Why it matters
Enveda's approach to drug discovery leverages AI to analyze mass spectrometry data and identify potential therapeutics in natural compounds. The company is advancing a program in Phase 2 trials and aims to bring new treatments to market. The financing round drew support from prominent investors, including Catalio Capital Management, Baillie Gifford, and Premji Invest.
What is confirmed
- Enveda raised $311 million in Series E funding.
- The financing round was led by Catalio Capital Management.
- Enveda's valuation is approximately $2 billion.
- The company is using AI to discover drugs in natural compounds.
- Enveda has a program in Phase 2 clinical trials.
- Existing backers Baillie Gifford and Premji participated in the round.
What to watch next
- Enveda's progress in Phase 2 clinical trials
- FDA approval for Enveda's nature-derived therapeutics
- commercialization of Enveda's AI-discovered drugs
confidence 90%Sources used for this update (6)
- www.spaqitech.com β AI biotech Enveda raises $311 million Series E, doubling ...
- www.ai-market-watch.com β Enveda raises $311 million to advance AI-discovered natural ...
- quasa.io β Enveda Raises $311M as Its AI Drugs Face Clinical Tests
- www.wortins.com β Enveda Biotech raises $311M Series E at $2B valuation
- www.trysignalbase.com β Enveda Biosciences Raises $311.0M Series E Round
- www.biospace.com β Funding - BioSpace
-
Enveda Secures $311 Million Series E Funding
Boulder-based clinical-stage biotechnology company Enveda closed a $311 million Series E financing round on September 23, 2026. The investment values the artificial intelligence drug discovery firm at $2 billion. Catalio Capital Management led the round, which included new contributions from Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a sovereign wealth fund, and Alderline Group. Existing backers Baillie Gifford and Premji also participated. The company plans to use the capital to push nature-derived therapeutics through clinical trials, focusing on skin conditions and maintaining weight loss after stopping GLP-1 drugs.
Why it matters
The company leverages artificial intelligence to discover new pharmaceutical products from natural chemistry. This massive Series E financing doubles the biotechnology firm's previous valuation and positions the organization to advance multiple drug candidates toward regulatory approval.
What is confirmed
- Enveda closed a $311 million Series E financing round led by Catalio Capital Management on September 23, 2026.
- The financing round values the biotechnology company at $2 billion.
- New investors in the round include Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, T. Rowe Price Investment Management accounts, Digitalis Ventures, a sovereign wealth fund, and Alderline Group.
- Existing investors Baillie Gifford and Premji participated in the Series E round.
- The firm is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1 treatments.
What to watch next
- Progress of nature-derived drug candidates entering clinical trials
- Specific clinical data regarding skin conditions and GLP-1 weight loss maintenance treatments
confidence 100%Sources used for this update (6)
- finance.yahoo.com β Enveda Raises $311 Million From Leading AI and Biotech ...
- www.financialcontent.com β Enveda Raises $311 Million From Leading AI and Biotech ...
- www.newsbreak.com β Enveda Raises $311 Million From Leading AI and Biotech ...
- techcrunch.com β Enveda secures $311M to bring more nature-derived AI drugs ...
- medicaex.com β Enveda Raises $311 Million From Leading AI and Biotech ...
- www.fiercebiotech.com β Enveda reaps $311M round to help become βhousehold nameβ
-
Enveda Secures $311 Million Series E Funding at $2 Billion Valuation
Biotech startup Enveda has raised $311 million in Series E funding to advance AI-discovered, nature-derived medicines. The funding round values the company at $2 billion, doubling its previous valuation. Enveda intends to use the capital to move more candidates into clinical trials, focusing specifically on inflammatory diseases and late-stage obesity treatments. The company aims to develop medicines that address life after GLP-1 drugs and seeks to establish itself as a household name in the pharmaceutical industry.
Why it matters
Enveda uses artificial intelligence to analyze the chemistry of the natural world for drug discovery. This approach seeks to modernize pharmaceutical development by integrating AI with nature-derived compounds. The current push into obesity and inflammatory diseases targets high-demand therapeutic areas.
What is confirmed
- Enveda raised $311 million in Series E funding.
- The company is now valued at $2 billion.
- Enveda uses AI to discover drugs from the natural world.
- The funding will support the development of medicines for obesity and inflammatory diseases.
Still unconfirmed
- Enveda's valuation has doubled to reach the $2 billion mark.
- The company is developing a drug specifically aimed at life after GLP-1 drugs.
- Enveda has an ambition to become a household name.
What to watch next
- Results from upcoming clinical trials for nature-derived AI drugs
- Specific naming of the candidates targeting obesity and inflammatory diseases
confidence 100%Sources used for this update (8)
- businesswire.com β Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century
- WSJ β Exclusive | AI Biotech Enveda Doubles in Value to $2 Billion
- BioSpace β AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
- TechCrunch β Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
- Fierce Biotech β Enveda reaps $311M series E to feed ambition to become a βhousehold nameβ
- digitalmarketreports.com β Enveda Raises $311 Million at $2 Billion Valuation to Advance AI-Discovered Drugs
- Longevity.Technology β Natureβs chemistry, read by AI, funded at $311m
- theaiinsider.tech β Enveda Raises $311M Series E at $2B Valuation to Advance AI-Discovered Natural Medicines
Community Sentiment: How do you assess this situation?
Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community